Pharma
Strides Pharma Science Ltd
STAR · NSE · INE939A01011Wednesday, 9 Sept 20263:02 pm
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE20.0%
ROCE18.3%
ROE20.0%
1Y Return+29.54%
Avg. Volume0.5M
Price Chart
52-Week Range
About
Strides Pharma Science Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹1,200.2
52W High / Low₹1,231 / ₹768.65
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE20.0%
1Y Return+29.54%
Day Change+1.08%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹5,004 Cr | ₹4,859 Cr | ₹4,565 Cr | ||||||||||
| Expenses | ₹4,070 Cr | ₹3,933 Cr | ₹3,763 Cr | ||||||||||
| Operating Profit | ₹935 Cr | ₹925 Cr | ₹803 Cr | ||||||||||
| OPM % | 19.0% | 19.0% | 18.0% | ||||||||||
| Other Income | ₹193 Cr | ₹124 Cr | ₹3,313 Cr | ||||||||||
| Depreciation | ₹210 Cr | ₹202 Cr | ₹192 Cr | ||||||||||
| Interest | ₹172 Cr | ₹179 Cr | ₹249 Cr | ||||||||||
| Profit Before Tax | ₹746 Cr | ₹669 Cr | ₹3,675 Cr | ||||||||||
| Tax | ₹112 Cr | ₹94 Cr | ₹77 Cr | ||||||||||
| Net Profit | ₹634 Cr | ₹575 Cr | ₹3,598 Cr | ||||||||||
| EPS (₹) | 66.6 | 60.3 | 389.8 | ||||||||||
| Dividend Payout % | — | 8% | 1% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹1,265 Cr | ₹1,323 Cr | ₹1,195 Cr | ₹1,221 Cr | |||||||||
| Expenses | ₹1,037 Cr | ₹1,084 Cr | ₹959 Cr | ₹990 Cr | |||||||||
| Operating Profit | ₹228 Cr | ₹240 Cr | ₹236 Cr | ₹231 Cr | |||||||||
| OPM % | 18.0% | 18.0% | 20.0% | 19.0% | |||||||||
| Depreciation | ₹56 Cr | ₹53 Cr | ₹51 Cr | ₹50 Cr | |||||||||
| Interest | ₹41 Cr | ₹42 Cr | ₹43 Cr | ₹46 Cr | |||||||||
| Net Profit | ₹165 Cr | ₹129 Cr | ₹208 Cr | ₹132 Cr | |||||||||
| EPS (₹) | 17.0 | 13.8 | 21.9 | 13.8 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹92 Cr | ₹92 Cr | ₹92 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹3,015 Cr | ₹2,460 Cr | ₹2,034 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹1,758 Cr | ₹1,880 Cr | ₹2,517 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1,942 Cr | ₹1,497 Cr | ₹1,156 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹6,807 Cr | ₹5,929 Cr | ₹5,799 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹2,101 Cr | ₹1,899 Cr | ₹1,865 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹291 Cr | ₹409 Cr | ₹303 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹3,967 Cr | ₹3,414 Cr | ₹3,470 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹6,807 Cr | ₹5,929 Cr | ₹5,799 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹703 Cr | ₹-173 Cr | ₹-453 Cr | ₹76 Cr |
| FY25 | ₹684 Cr | ₹-90 Cr | ₹-643 Cr | ₹-48 Cr |
| FY24 | ₹701 Cr | ₹-150 Cr | ₹-693 Cr | ₹-142 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Cipla Ltd | — | — | +11.77% | -5.50% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-04Global Softgel Capsules Market to Reach $12.49 Billion by 2031 as Pharmaceutical and Nutraceutical Demand Accelerates - Catalent, Lonza, Procaps Group, Aenova Group, and Sirio Pharma Lead the IndustryGlobeNewswire2026-08-19Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseBSE Filing2026-08-04Strides Pharma Science Ltd (BOM:532531) (Q1 FY27) Earnings Call Highlights: Ex-US Growth Drives ...GuruFocus.com2026-06-17Strides Pharma Science Ltd (BOM:532531) Q4 2026 Earnings Call Highlights: Record EBITDA and ...GuruFocus.com
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.